With Digital PCR, the Rare Becomes Routine
Applications Which Bring Rare Events to Light Are Proliferating
Mass Spec Is Being Souped Up to Help It Keep Up
A Few Modifications Might Enhance Performance
Beyond Short Reads
Up-and-Coming Genomics Technologies Reveal Previously Unseen Structural Variants
The Scoop: St. Jude to Build a Collab-Fostering Research Hub
Ground Will Be Broken for a 625,000-Square-Foot Facility to Be Completed in 2021
For full access to this article login to GEN Select now.
Ready, Aim, CRISPR (or RNAi)
When targeting genes, drug developers may opt for knockdown via CRISPR or silencing via RNAi. These weapons, however, may fit different battle plans.
- Recent progress in probing gene function via the RNAi and CRISPR methods were a strong theme of the Discovery On Target conference, which took place last month in Boston. Both methods enable researchers to impair the function of a targeted gene. With RNAi (short for RNA interference), molecules ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.